ViewRay, Inc. (VRAY): Price and Financial Metrics
VRAY Price/Volume Stats
Current price | $0.03 | 52-week high | $4.96 |
Prev. close | $0.04 | 52-week low | $0.02 |
Day low | $0.02 | Volume | 108,502,700 |
Day high | $0.04 | Avg. volume | 7,510,055 |
50-day MA | $0.43 | Dividend yield | N/A |
200-day MA | $2.97 | Market Cap | 4.59M |
VRAY Stock Price Chart Interactive Chart >
VRAY POWR Grades
- Sentiment is the dimension where VRAY ranks best; there it ranks ahead of 66.46% of US stocks.
- The strongest trend for VRAY is in Value, which has been heading up over the past 149 days.
- VRAY's current lowest rank is in the Stability metric (where it is better than 5.52% of US stocks).
VRAY Stock Summary
- Revenue growth over the past 12 months for VIEWRAY INC comes in at 44.09%, a number that bests 85.69% of the US stocks we're tracking.
- The volatility of VIEWRAY INC's share price is greater than that of 94.83% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VRAY comes in at -26.61% -- higher than that of just 15.47% of stocks in our set.
- Stocks that are quantitatively similar to VRAY, based on their financial statements, market capitalization, and price volatility, are OM, TBLA, PHR, MXCT, and CRCT.
- VRAY's SEC filings can be seen here. And to visit VIEWRAY INC's official web site, go to www.viewray.com.
VRAY Valuation Summary
- VRAY's price/sales ratio is 0.6; this is 87.5% lower than that of the median Healthcare stock.
- Over the past 88 months, VRAY's price/earnings ratio has gone up 3.
Below are key valuation metrics over time for VRAY.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
VRAY | 2023-06-28 | 0.6 | 1.2 | -0.6 | -0.6 |
VRAY | 2023-06-27 | 0.7 | 1.3 | -0.6 | -0.6 |
VRAY | 2023-06-26 | 0.7 | 1.3 | -0.7 | -0.7 |
VRAY | 2023-06-23 | 0.7 | 1.3 | -0.6 | -0.6 |
VRAY | 2023-06-22 | 0.6 | 1.2 | -0.6 | -0.6 |
VRAY | 2023-06-21 | 0.7 | 1.4 | -0.7 | -0.7 |
VRAY Growth Metrics
- Its 4 year cash and equivalents growth rate is now at 280.75%.
- The 5 year revenue growth rate now stands at 353.95%.
- Its 3 year cash and equivalents growth rate is now at 25.46%.

The table below shows VRAY's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 87.902 | -74.412 | -106.582 |
2022-06-30 | 80.589 | -76.112 | -105.736 |
2022-03-31 | 73.47 | -68.169 | -109.079 |
2021-12-31 | 70.119 | -62.091 | -110.048 |
2021-09-30 | 68.189 | -60.183 | -109.079 |
2021-06-30 | 59.098 | -58.768 | -111.943 |
VRAY's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VRAY has a Quality Grade of F, ranking ahead of 4.3% of graded US stocks.
- VRAY's asset turnover comes in at 0.212 -- ranking 141st of 186 Medical Equipment stocks.
- DXCM, SRTS, and SMTI are the stocks whose asset turnover ratios are most correlated with VRAY.
The table below shows VRAY's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.212 | -0.038 | -0.931 |
2021-03-31 | 0.204 | -0.028 | -0.887 |
2020-12-31 | 0.194 | -0.071 | -0.869 |
2020-09-30 | 0.174 | -0.148 | -0.903 |
2020-06-30 | 0.218 | -0.099 | -0.769 |
2020-03-31 | 0.278 | -0.027 | -0.752 |
VRAY Price Target
For more insight on analysts targets of VRAY, see our VRAY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $5.88 | Average Broker Recommendation | 1.29 (Strong Buy) |
ViewRay, Inc. (VRAY) Company Bio
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems worldwide. It offers MRIdian, a MRI-guided radiation therapy system that images and treats cancer patients simultaneously. MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. The company markets its MRIdian through a direct sales force in the United States and distributors worldwide to a range of customers, including university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. was founded in 2004 and is based in Oakwood Village, Ohio.
Latest VRAY News From Around the Web
Below are the latest news stories about VIEWRAY INC that investors may wish to consider to help them evaluate VRAY as an investment opportunity.
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy SystemViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA Medical Center. This will be the first cancer center in Oklahoma and the fourth VA medical center offering Veterans access to MRIdian's advanced MRI-guided radiation therapy to treat cancer. The MRIdian system will enable the Oklahoma City VA Medical Center to provide precision MRI-guided rad |
Do You Believe in the Growth Prospects of ViewRay (VRAY)?Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The fund was up 11.20% in the first quarter compared to the Russell 2000 Growth Index’s return of 6.07%. The strong performance of holdings in the Information Technology (IT), Industrials, and […] |
ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology MeetingViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) with over 50 presentations and posters highlighting MRIdian clinical and research experience. This year's ESTRO meeting will be held May 12-16, 2023, in Vienna, Austria. |
Need To Know: The Consensus Just Cut Its ViewRay, Inc. (NASDAQ:VRAY) Estimates For 2023The latest analyst coverage could presage a bad day for ViewRay, Inc. ( NASDAQ:VRAY ), with the analysts making... |
Q1 2023 ViewRay Inc Earnings CallQ1 2023 ViewRay Inc Earnings Call |
VRAY Price Returns
1-mo | N/A |
3-mo | -92.09% |
6-mo | -99.10% |
1-year | -99.19% |
3-year | -99.05% |
5-year | -99.68% |
YTD | -99.33% |
2022 | -18.69% |
2021 | 44.24% |
2020 | -9.48% |
2019 | -30.48% |
2018 | -34.45% |
Continue Researching VRAY
Here are a few links from around the web to help you further your research on ViewRay Inc's stock as an investment opportunity:ViewRay Inc (VRAY) Stock Price | Nasdaq
ViewRay Inc (VRAY) Stock Quote, History and News - Yahoo Finance
ViewRay Inc (VRAY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...